menu
    • menu
    [{"orgOrder":0,"company":"ColonaryConcepts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Macrogol","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ColonaryConcepts","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"ColonaryConcepts \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ColonaryConcepts \/ Not Applicable"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Macrogol","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"NovaBay Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NovaBay Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Macrogol","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"EA Pharma \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"EA Pharma \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Macrogol","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.11,"dosageForm":"Solution\/Drops","sponsorNew":"Johnson & Johnson \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson \/ Bausch & Lomb Incorporated"}]

    Find Clinical Drug Pipeline Developments & Deals for Polyethylene Glycol

    Menu

    Polyethylene Glycol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Johnson & Johnson

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Johnson & Johnson

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macrogol

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Bausch & Lomb Incorporated

                            Deal Size : $106.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bausch + Lomb Expands OTC Product Line with Acquisition of Blink® Eye Drops

                            Details : Through the acquisition, Bausch & Lomb expands its OTC product line by obtaining Blink portfolio of eye drops including, Blink® Tears (polyethylene glycol).

                            Brand Name : Blink® Tears

                            Molecule Type : Small molecule

                            Upfront Cash : $106.5 million

                            July 06, 2023

                            Lead Product(s) : Macrogol

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Bausch & Lomb Incorporated

                            Deal Size : $106.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EA Pharma

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            EA Pharma

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macrogol

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Mochida Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            “MOVICOL® HD” Launched - A New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment fo...

                            Details : MOVICOL® HD is a high dose formulation of existing “MOVICOL® LD”, the first polyethylene glycol indicated for treatment of chronic constipation1) in Japan. MOVICOL® HD contains the same active ingredients in double the quantity of MOVICOL® LD per...

                            Brand Name : Movicol HD

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 20, 2022

                            Lead Product(s) : Macrogol

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Mochida Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NovaBay Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            NovaBay Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macrogol,Polypropylene Glycol

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NovaBay Pharmaceuticals Expands Its Eyecare Product Portfolio With the Launch of Lubricating Eye Drops for the...

                            Details : New Avenova (Polyethylene Glycol) lubricating eye drops are the first-line, go-to product for treating the symptoms of dry eye because they can provide immediate relief from the discomfort and pain that’s often associated with this common condition.

                            Brand Name : Avenova

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 10, 2022

                            Lead Product(s) : Macrogol,Polypropylene Glycol

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ColonaryConcepts

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ColonaryConcepts

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macrogol,Electrolytes

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Phase 2B Study of ColonaryConcepts’ Novel Colonoscopy Prep Confirms Excellent Efficacy & Safety Higher Patie...

                            Details : The investigational prep is designed to be good-tasting and easy-to-consume, with no fasting and lower fluid requirements than standard preps.

                            Brand Name : Colonoscopy prep

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 21, 2020

                            Lead Product(s) : Macrogol,Electrolytes

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth